Gilead Sciences, Inc.

Kronos Bio, Inc.

Sierra Oncology, Inc.

Henry G Morrison

Bing Shi

Dimitrios Stefanidis

Fang Wang

Ernest A Carra

Jeffrey N Hemenway

Matthew Robert Warr

James Andrew Whitney

Yan Xin

Olga Viktorovna Lapina

Brandon Heath Brown

Katie Ann Keaton

Peter C Fung

Troy Evan Reynolds

Johann Chan

Dominika Pcion

Peter Chee-Chu Fung

Jesper Alexis Jernelius

Brandon H Brown

Troy Reynolds

Dustin Bringley

Sylvie M Asselin

Paul Robert Hartmeier

Christopher S Regens

Tiago Vieira

Pavel Robertovich Badalov

Tim G Elford

Pavel R Badalov

Polymorphs of a bis-mesylate salt of a compound of Formula IA: are provided. Also provided are process for making the polymorphs and methods of use thereof.

Hydrates of polymorphs of 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-a]pyrazin-8-amine bis-mesylate as Syk inhibitors

The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide

The present disclosure provides crystalline forms, solvates and hydrates of (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol, and methods of making.

Solid forms of a toll-like receptor modulator

The present disclosure provides solid forms, solvates and hydrates of (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol, and methods of making.

Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors

Crystalline forms of the anti-HCV compound (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.

Crystalline forms of an antiviral compound

(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide

Growing community of inventors

Dublin, CA, United States of America

Henry G Morrison